Spyre Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SYRE research report →
About the company
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin.
- CEO
- Cameron Turtle
- IPO
- 2016
- Employees
- 73
- HQ
- Waltham, MA, US
Price Chart
- Market Cap
- $5.23B
- P/E
- -39.74
- P/S
- 57.82
- P/B
- 44.69
- EV/EBITDA
- -26.38
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- -255.97%
- Net Margin
- -198.28%
- ROE
- -31.25%
- ROIC
- -34.12%
- Revenue
- $0 · 0.00%
- Net Income
- $-155,203,000 · 25.39%
- EPS
- $-1.98 · 37.74%
- Op Income
- $-209,562,000
- FCF YoY
- -7.52%
- 52W High
- $102.06
- 52W Low
- $14.51
- 50D MA
- $77.29
- 200D MA
- $44.23
- Beta
- 3.02
- Avg Volume
- 1.45M
Get TickerSpark's AI analysis on SYRE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | Burrows Scott L | other | 7,500 |
| Jul 1, 26 | Burrows Scott L | other | 7,500 |
| Jul 1, 26 | Burrows Scott L | sell | 5,775 |
| Jul 1, 26 | Burrows Scott L | sell | 1,725 |
| Jul 1, 26 | Sloan Sheldon | other | 8,334 |
| Jul 1, 26 | Sloan Sheldon | other | 8,334 |
| Jul 1, 26 | Sloan Sheldon | sell | 6,500 |
| Jul 1, 26 | Sloan Sheldon | sell | 1,834 |
| Jul 1, 26 | Turtle Cameron | sell | 10,176 |
| Jul 1, 26 | Turtle Cameron | sell | 4,234 |
Our SYRE coverage
Recent articles, reports, and earnings notes.
No research on SYRE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SYRE report →Similar companies
Peers in the same neighborhood.